Cabaletta Bio, Inc. — FY2020 Form 10-K Summary
Business context and reporting period
Cabaletta Bio is a clinical-stage biotechnology company developing engineered CAAR T-cell therapies intended to selectively eliminate pathogenic B cells involved in autoimmune and alloimmune diseases. The filing covers the fiscal year ended December 31, 2020, with comparative results for 2019. The company had 34 employees, including 33 full-time employees, at year-end.
The lead program, DSG3-CAART, targets mucosal pemphigus vulgaris and entered a Phase 1 DesCAARTes trial in 2020. The first patient was dosed in December 2020. Other programs included preclinical MuSK-CAART for MuSK myasthenia gravis, DSG3/1-CAART for mucocutaneous pemphigus vulgaris, and FVIII-CAART for Hemophilia A patients with FVIII alloantibodies.
Financial and operating metrics
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Research and development expense | $21.4 million | $11.7 million | +$9.7 million |
| General and administrative expense | $12.5 million | $7.0 million | +$5.5 million |
| Total operating expenses | $33.8 million | $18.7 million | +$15.2 million |
| Loss from operations | $(33.8) million | $(18.7) million | Wider loss |
| Interest income | $0.5 million | $1.7 million | $(1.2) million |
| Net loss | $(33.3) million | $(16.9) million | $(16.4) million |
| Net loss per share | $(1.44) | $(4.07) | Improved due primarily to increased share count |
| Operating cash flow | $(26.8) million | $(16.0) million | Higher cash use |
| Cash, cash equivalents and investments | $108.7 million | $136.2 million cash and equivalents | Lower liquidity balance |
| Accumulated deficit | $66.3 million | $33.0 million | +$33.3 million |
Gross margin, operating margin and net margin are not meaningful because the company generated no revenue. The filing does not disclose outstanding debt or a credit facility; liquidity was primarily funded by equity capital and investments.
At December 31, 2020, the company had $101.4 million of cash and cash equivalents, $7.2 million of short-term investments, $5.2 million of current liabilities and $109.5 million of stockholders’ equity. Capital expenditures were $0.6 million. Investing cash outflows were $8.0 million, primarily for purchases of investments and property and equipment.
Material changes versus the prior comparable period
- Research and development expense increased 83%, driven by higher personnel costs, manufacturing and vector-related activities, outsourced development work, sponsored research and clinical trial costs.
- General and administrative expense increased 78%, reflecting higher personnel and stock-based compensation costs, public-company insurance, legal, accounting, recruiting and other professional services.
- Net loss nearly doubled as the company advanced DSG3-CAART into clinical testing and expanded its development infrastructure.
- Operating cash use increased to $26.8 million from $16.0 million, while the company invested $11.1 million in short-term investments and received $3.8 million from investment maturities.
- Cash and investments declined to $108.7 million from $136.2 million at December 31, 2019. The company continued to have no product revenue and no commercialized products.
- The company entered into a $75.0 million at-the-market equity sales agreement in November 2020; no shares had been sold under the agreement by year-end.
- In May 2020, the Penn license and sponsored research arrangements were amended or expanded. The company also entered into a collaboration with Artisan Bio in July 2020 to evaluate gene-editing and engineering technology for certain pipeline products.
Guidance, outlook, risks and unusual items
- Management expected existing cash, cash equivalents and investments to fund operations through at least the third quarter of 2022, based on its operating plan. The filing also states that liquidity was expected to fund projected operations for at least 12 months from the filing date.
- The company expects substantial additional financing to complete the Phase 1 DSG3-CAART program, advance other candidates, develop manufacturing capabilities and fund ongoing operations. Future financing may involve equity dilution, debt, collaborations or licensing transactions.
- Management expected acute safety data from the first DesCAARTes cohort in the first half of 2021 and additional topline data from completed dose cohorts during the second half of 2021. An IND submission for MuSK-CAART was expected in the second half of 2021.
- The company remains highly dependent on Penn and affiliated entities for research, clinical support, manufacturing capacity and technology transfer. The Penn Services Agreement was scheduled to expire no earlier than October 19, 2021, subject to completion of services and termination rights.
- Manufacturing is complex, patient-specific and not commercially validated. Penn cannot provide clinical supply for late-phase trials, requiring future transfers to contract manufacturing organizations and, potentially, construction of an internal facility.
- In January 2021, the company entered into a WuXi agreement for cell processing for the anticipated MuSK-CAART Phase 1 trial. Termination for convenience could require a $1.5 million fee. In February 2021, it entered into a $0.7 million CHOP vector-manufacturing agreement.
- Material clinical risks include cytokine release syndrome, neurotoxicity, off-target tissue effects, inadequate target engagement, adverse immune reactions and the possibility that preclinical results will not predict clinical outcomes.
- COVID-19 had not significantly affected FY2020 financial results, but management warned that the pandemic could disrupt patient enrollment, clinical sites, manufacturing, suppliers, shipping, staffing and access to capital.
- The company has incurred losses in every period since inception and does not expect product revenue for several years, if at all. Its ability to continue operations depends on successful development, regulatory approval, financing and eventual commercialization.
- The company recorded $4.4 million of stock-based compensation in FY2020 and had $9.8 million of unrecognized compensation expense related to unvested options at year-end.
- The company had federal, state and local net operating loss carryforwards of approximately $45.6 million, $47.7 million and $38.6 million, respectively, but maintained a full valuation allowance against deferred tax assets.
Most important facts for an investor to verify
- Whether the DesCAARTes trial demonstrates acceptable safety, target engagement and clinical activity, including the incidence and severity of cytokine release syndrome or other serious adverse events.
- Actual cash burn, investment balances and financing runway relative to management’s expectation of funding operations through at least the third quarter of 2022.
- The timing, pricing and dilution implications of future equity financings, including potential use of the $75.0 million at-the-market facility.
- Whether Penn and contract manufacturers can provide reliable, scalable and comparable clinical supply, and whether technology transfer milestones are achieved.
- Progress toward the MuSK-CAART IND submission and development of DSG3/1-CAART, FVIII-CAART and other pipeline candidates.
- The enforceability and continuing availability of the Penn-licensed intellectual property, including compliance with diligence, milestone and royalty obligations.
- Whether the company can obtain regulatory approval for any CAAR T-cell product and ultimately establish reimbursement, manufacturing economics and commercial demand.
- The effect of COVID-19 and other operational disruptions on clinical enrollment, manufacturing capacity, trial timelines and future capital access.